Xavier Montalban, MD, PhD, BA, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the safety and efficacy of the BTK inhibitor evobrutinib in multiple sclerosis (MS). Previously, there has been a lot of debate concerning the safety of BTK inhibitors across various diseases. However, with the increasing specificity of BTK inhibitors in MS trials, results have demonstrated positive safety and efficacy results for evobrutinib in MS treatment – leading to three current Phase III clinical trials. With the assessment of evobrutinib over the past 2.5 years from an open-label extension of the Phase II trials, positive results demonstrate great potential for this BTK inhibitor in MS treatment. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.
Dr Montalban has received speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.